Trial Profile
efficacy and safety of Gemcitabine plus nab-paclitaxel in unresectable pancreas cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Mar 2022
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Carcinoma; Ductal carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 26 Feb 2022 Status changed from recruiting to discontinued.
- 25 Dec 2014 New trial record